Format

Send to

Choose Destination
Leukemia. 2014 Feb;28(2):404-7. doi: 10.1038/leu.2013.205. Epub 2013 Jul 4.

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).

Author information

1
Department of Biochemistry, University of Zürich, Zürich, Switzerland.
2
Swiss Institute for Experimental Cancer Research, School of Life Sciences, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.
3
Brain Mind Institute, School of Life Sciences, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.

Erratum in

  • Leukemia. 2014 Feb;28(2):471-2.
PMID:
23823659
DOI:
10.1038/leu.2013.205
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center